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Heterozygous, de novo mutations in the glial fibrillary acidic protein (GFAP) gene have recently been reported in
12 patients affected by neuropathologically proved Alexander disease. We searched for GFAP mutations in a series
of patients who had heterogeneous clinical symptoms but were candidates for Alexander disease on the basis of
suggestive neuroimaging abnormalities. Missense, heterozygous, de novo GFAP mutations were found in exons 1
or 4 for 14 of the 15 patients analyzed, including patients without macrocephaly. Nine patients carried arginine
mutations (four had R79H; four had R239C; and one had R239H) that have been described elsewhere, whereas
the other five had one of four novel mutations, of which two affect arginine (2R88C and 1R88S) and two affect
nonarginine residues (1L76F and 1N77Y). All mutations were located in the rod domain of GFAP, and there is a
correlation between clinical severity and the affected amino acid. These results confirm that GFAP mutations are
a reliable molecular marker for the diagnosis of infantile Alexander disease, and they also form a basis for the
recommendation of GFAP analysis for prenatal diagnosis to detect potential cases of germinal mosaicism.
In 1949, W. Stewart Alexander described a “progressive
fibrinoid degeneration of fibrillary astrocytes associated
with mental retardation in a hydrocephalic infant” (Al-
exander 1949) and suggested that the primary patho-
genesis was a specific dysfunction of astrocytes. Since
this first description, the dysfunction of astrocytes has
been observed in various age groups, with diverse symp-
toms (Russo et al. 1976; Borrett and Becker 1985; Prid-
more et al. 1993; Springer et al. 2000; Messing et al.
2001). Histologically, Alexander disease (MIM 203450)
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is characterized by the presence in astrocytes of cyto-
plasmic inclusions, termed “Rosenthal fibers.” These in-
clusions, which contain the intermediate filament protein
GFAP (MIM 137780) in association with small heat-
shock proteins, are found predominately in astrocytes
located in subependymal, subpial, and periventricular
areas. The disease is also usually associated with myelin
loss in a rostrocaudal gradient. The most notable fea-
tures of the infantile form of Alexander disease, which
begins during the first two years of life, are macrocephaly
(and sometimes hydrocephaly), psychomotor regression,
seizures, and spasticity. The patient dies within the first
decade. MRI is useful for diagnosis and shows signaling
changes in white matter, with frontal predominance, and
in some patients abnormalities of the basal ganglia and
the thalamus, contrast enhancement, and variable en-
largement of the ventricles (Pridmore et al. 1993; John-
son et al. 1996; Springer et al. 2000; van der Knaap et
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al. 2001). On the basis of the presence of Rosenthal
fibers, juvenile and adult forms have been identified. Ju-
venile patients have a slower clinical course (with bulbar
signs, ataxia, and spasticity), and their intellectual abil-
ities are usually preserved (Russo et al. 1976; Borrett
and Becker 1985; Reichard et al. 1996). Adult patients
have heterogeneous symptoms; some patients have re-
lapsing-remitting neurological symptoms that mimic
multiple sclerosis and are only diagnosed as Alexander
disease during neuropathological examination (Seil et al.
1968; Herndon et al. 1970; Howard et al. 1993;
Schwankhaus et al. 1995). Most of the neuropathol-
ogically proved cases of Alexander disease are sporadic,
but rare familial cases have been reported (reviewed by
Messing et al. 2001). In adults, an autosomal dominant
mode of inheritance has been suggested (Howard et al.
1993; Schwankhaus et al. 1995), whereas recessive
transmission has been postulated for the few described
infants who have affected siblings (Wohlwill et al. 1959;
Springer 2000).
The genetic origin of this disease was still controversial
when Rosenthal fibers, indistinguishable from those de-
scribed in Alexander disease, were found in the brain
tissue of transgenic mice overexpressing human GFAP
(Messing et al. 1998; Eng et al. 1998). Thus, the GFAP
gene became a good candidate for Alexander disease,
and missense mutations were found in 10 of 11 sporadic,
mostly infantile, neuropathologically proved cases in
which the GFAP coding region was sequenced (Brenner
et al. 2001). All these mutations were heterozygous, ap-
peared de novo, and affected only arginine residues.
We evaluated the GFAP gene for mutations in 15
patients with sporadic infantile disease. Although they
had heterogeneous clinical presentations, all 15 pa-
tients had MRI abnormalities suggestive of Alexander
disease, and 4 had neuropathologically proved Al-
exander disease (table 1).
In six patients (patients 1, 7, 8, 10, 14, and 15), the
diagnosis of infantile Alexander disease was suspected
on the basis of typical clinical presentation characterized
by onset at age !6 mo, delay or deterioration of psy-
chomotor development, and the presence of seizures and
progressive megalencephaly. In all six patients, typical
abnormalities, with a rostrocaudal gradient of the ab-
normal white matter signal, were observed with the use
of cerebral CT scanning and MRI (fig. 1A). Diagnosis
was confirmed in three patients by the presence of Ro-
senthal fibers in tissue samples taken during postmortem
examination (patients 14 and 15) or brain biopsy (pa-
tient 1) (fig. 1C). For these three patients, the disease
course was particularly severe, with onset by age 4 mo,
feeding and respiratory difficulties at age 12–24 mo, re-
current seizures, and death at age 15–65 mo. Patient 15
was especially severely affected by hydrocephalus and
refractory seizures.
In the other nine patients, clinical features were less
significant. In patient 12, head circumference was nor-
mal, but the course of the disease was severe. In a pattern
similar to that of the first group of patients, patient 12
had early psychomotor degradation and recurrent sei-
zures (which appeared at age 13 mo), and death occurred
at age 53 mo, with postmortem confirmation of the di-
agnosis. The eight remaining patients were referred to a
neuropediatric unit, either because of seizures (patients
4 and 6) or because of delayed psychomotor develop-
ment (patients 2, 3, 5, 9, 11, and 13). None had spas-
ticity or ataxia until age 18 mo, and only one had a
progressive macrocephaly, observed after the age of 1
year (patient 11). A diagnosis of Alexander disease was
suspected when (1) MRI or CT demonstrated an ab-
normal white matter signal, clearly predominant in the
frontal regions, similar to those found in the first group
of patients (fig. 1B); and (2) negative results of wide-
spread metabolic screening ruled out known causes of
leukodystrophies (especially Canavan, mitochondrial,
lysosomal, and peroxysomal diseases). During follow-
up, five patients (patients 3–6 and 13) have had only
occasional seizures, and three had no epilepsy (patients
2, 9, and 11). All made initial psychomotor progress,
three achieving independent walking and the use of a
few words (patients 3, 5, and 6). However, three patients
(patients 3, 6, and 13) subsequently developed slowly
progressive impairment of motor and intellectual abili-
ties, with onset at age 6–8 years. All eight of these pa-
tients are still alive at age 1.5–20 years.
Blood samples from the affected patients—and from
parents, when available—were collected after obtaining
informed consent. For the first nine patients (patients
1–5, 7, 10, 14, and 15), each of the nine GFAP exons
was amplified and sequenced (conditions and primers
available on request). GFAP mutations were found in
eight of these patients (table 1). Each of these mutations
was either in exon 1 or 4, and most were the same as
ones described elsewhere, which resulted in the loss of
an AciI restriction site (Brenner et al. 2001). Because a
mutation that removed an AciI site had also previously
been found in exon 8, exons 1, 4, and 8 were first am-
plified and tested for a change in the AciI digestion pat-
tern for the remaining six patients. When a modified
restriction pattern was observed, the corresponding exon
was sequenced. When no modification was observed, the
three exons were sequenced. Using this approach, we
found mutations for each of the remaining six patients.
Each of the 14 mutations detected was present in the
heterozygous state, and 9 involved two of the previously
reported arginine residues (four patients with R79 and
five patients with R239); however, in five patients we
discovered four novel nonconservative mutations, all lo-
cated in the first exon: L76F, N77Y, R88C (two patients),
and R88S (fig. 2A). None of these mutations was found
Table 1
Clinical Features and GFAP Mutations of Patients with Progressive Fibrinoid Degeneration
PATIENT
AGE AT
ONSET
(mo)
PSYCHOMOTOR
DEVELOPMENT
HEAD
CIRCUMFERENCEa SEIZURESb
STATUS AND AGE
AT FOLLOW-UP
OR DEATH
(years)
NEURO-
PATHLOGY EXON DOMAIN
NUCLEOTIDE
CHANGEc
AMINO
ACID
CHANGEd
RESTRICTION
SITE PARENTSe
Delay
(mo) Degradation
1 4 … 4 mo 3  Dead (5.4)  1 1A 240CrT L76F* SacI NAf
2 4 8 … 1 … Alive (1.5) … 1 1A 243ArT N77Y* … 2 nl
3 Birth Birth 7 years 1  Alive (7.5) … 1 1A 250GrA R79H AciI 2 nl
4 8 8 … 1.5  Alive (2.6) … 1 1A 250GrA R79H AciI …
5 6 6 … 0.5  Alive (4.7) … 1 1A 250GrA R79H AciI 2 nl
6 6 6 8 years 1.5  Alive (20) … 1 1A 250GrA R79H AciI …
7 3 6 … 3  Alive (5.5) … 1 1A 276CrT R88C* … 2 nl
8 Birth Birth … 3  Alive (2.5) … 1 1A 276CrT R88C* … 2 nl
9 1 1 … 1 … Alive (3.5) … 1 1A 276CrA R88S* … …
10 6 6 … 3  Alive (2.2) … 4 2A 729CrT R239C AciI 2 nl
11 6 6 … 3.5 … Alive (2) … 4 2A 729CrT R239C AciI 2 nl
12 9 12 13 mo 1  Dead (4.5)  4 2A 729CrT R239C AciI 2 nl
13 18 18 6 years 1.5  Alive (8) … 4 2A 729CrT R239C AciI 1 nl
14 3 … 3 mo 3  Dead (1.2)  4 2A 730GrA R239H AciI 2 nl
15 4 4 8 mo 4  Dead (2.5)  … … None … … …
a Expressed as standard deviations above the mean.
b  p Occasional seizures;  p recurrent seizures; and  p severe seizures.
c Nucleotide numbers refer to the cDNA sequence reported in Brenner et al. (1990).
d * p Novel mutations.
e nl p Normal for the mutation in question.
f NA p Not available. Parental DNA was not available; however, the mutation was absent in 50 control samples.
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Figure 1 A and B, Typical T2-weighted MRI images of brains of patients with infantile Alexander disease. A, Classical form (patient 7).
B, Mild form (patient 3). Note that both patients show the high signal intensity of white matter, predominately in the frontal area, and of the
basal ganglia. C, Rosenthal fiber in Alexander disease viewed by electron microscopy (patient 15); original magnification #28,500.
in the DNA samples of the 19 parents analyzed by re-
striction digestion or sequencing, including the parents
of the patients with the N77Y and R88C mutations.
Because parents were not available for the patient with
the L76F mutation, we tested for its presence in 50 con-
trol DNA samples, by SacI restriction digestion (fig. 2B).
All were negative.
Together with the results we reported elsewhere (Bren-
ner et al. 2001), analysis of the GFAP coding region of
patients diagnosed with Alexander disease has revealed
mutations in 26 of 28 patients (tables 1 and 2). All of
these mutations involve exons 1 (50%), 4 (42%), or 8
(8%); and 81% of the mutations involve loss of an AciI
restriction site. Therefore, detection of GFAP mutations
represents a valuable diagnostic tool for infantile Al-
exander disease, and GFAP mutations are detected in
93% of patients by amplification of only exons 1, 4,
and 8.
All the mutations we have identified involve amino
acids that are identical among human, rat, and mouse
GFAP, as well as many other intermediate filaments.
Each occurs within the helical-rod domain of GFAP (fig.
2C), which is highly conserved among intermediate fil-
aments and is essential for dimerization and organiza-
tion into a filament network (Fuchs and Cleveland
1998). It has been noted that there are disease-associated
mutations in other intermediate filaments homologous
to each of those previously reported for GFAP (Quinlan
2001). This is also the case for the new L76 and N77
mutations reported in the present study (e.g., Bonifas et
al. 1994; Endo et al. 1997). We have not found any
report of a mutation in an arginine homologous to R88;
but keratin 9 (MIM 144200), which has a Q at this
position, does have a disease-associated mutation at this
site (Hennies et al. 1994).
Clinical heterogeneity (including patients without
macrocephaly and those with less-severe courses) has
been described elsewhere in patients with Alexander dis-
ease diagnosed according to neuropathological criteria
or, more recently, according to MRI criteria (Russo et
al. 1976; Borrett and Becker 1985; Pridmore et al. 1993;
Springer et al. 2000; van der Knaap et al. 2001). Our
results validate these diagnoses by finding GFAP mu-
tations in a large percentage of patients who had het-
erogeneous clinical symptoms but were candidates for
Alexander disease on the basis of suggestive neuroim-
aging abnormalities. Many of these mutations were iden-
tical to those previously found for pathologically diag-
nosed Alexander disease, and the others fell into the
same pattern observed in the neuropathologically proved
cases: missense mutations that are heterozygous and
nonconservative and that arise de novo.
A genotype-phenotype correlation can be discerned
for the two most frequently mutated arginine residues
(R79 [8 patients] and R239 [10 patients]), with the phe-
notype of the R79 mutations appearing much less severe
than that of the R239 mutations (table 2). The number
of patients with other mutations is too small to deter-
mine a phenotypic pattern (table 1 and 2); however, the
four patients we found with R79 mutations appear to
be the least-severely affected: none developed macro-
cephaly, three achieved independent walking, and, at
the time of writing, all are alive at age 2.5–20 years.
Similarly, among the four patients with R79 mutations
who were reported by Brenner et al. (2001), two lived
until the ages of 14 and 48 years, and the other two
were still alive, at ages 7 and 8 years, when the article
was published.
In sharp contrast, our five patients with R239 mu-
tations had a marked impairment of psychomotor de-
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Figure 2 A, Identification of novel mutations in the GFAP gene in four patients with Alexander disease. Segments of the sequencing
chromatograms in the region of each mutated nucleotide are shown, with the site of the heterozygous point mutation indicated by an arrow.
B, Confirmation of the heterozygous 240CrT point mutation by RFLP analysis. This point mutation results in the loss of a restriction site for
SacI. Digestion of a PCR-amplified fragment of genomic DNA from control subjects produced three fragments of 368, 280, and 39 bp (C1
and C2). RFLP analysis of the affected individual generated four fragments of 648, 368, 280, and 39 bp; the 648-bp fragment (368 bp  280
bp) arose from loss of the SacI site on one of the chromosomes (case 1). The 39-bp restriction fragment is not shown in this gel. ND p
nondigested PCR-amplified fragment. C, Schematic representation of the GFAP gene and the corresponding protein, showing the localization
of mutations in Alexander disease. The nine exons of the GFAP gene are represented by boxes, and introns are represented by lines. Multiple
occurrences of a mutation are indicated by the number shown in parentheses, and mutations described elsewhere (Brenner et al. 2001) are
shown in blue. Mutations are clustered within exons encoding the rod domain of GFAP.
velopment, and three had progressive macrocephaly.
Similarly severe phenotypes were displayed by the pa-
tients with R239 who were reported by Brenner et al.
(2001). Interestingly, the single patient in the present
study and the single patient reported by Brenner et al.
(2001) who carried an R239H mutation had especially
severe clinical courses. Our patient (patient 14) acquired
only reactive smiling and head control, with early re-
gression and feeding and respiratory difficulties that led
to death at age 15 mo. Similarly, the single patient of
Brenner et al. (2001) who had R239H died at age 11
mo. In the two studies, the eight patients who had the
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Table 2
Severity of the Disease According to the Type of GFAP Mutation:
Results Obtained among Patients in the Present Study and among
Patients Reported by Brenner et al.
Amino
Acid
Change Patienta Macrocephalyb
Disease
Duration
(years) Status Severityc
L76F 1  5 Dead 
N77Y 2  1.2 Alive NR
R79H 3  7.5 Alive 0
R79H 4  2 Alive 
R79H 5  4 Alive 
R79H 6  20 Alive 
R79H 2* NA 38 Dead 
R79H 13*  12 Alive 
R79C 1* NA 14 Dead 
R79C 12* NA 6 Alive 
R88C 7  5 Alive 
R88C 8  2.5 Alive 
R88S 9  3.5 Alive 
R239C 10  1.7 Alive 
R239C 11  1.5 Alive 
R239C 12 0 3.5 Dead 
R239C 13 0 6.5 Alive 
R239C 3* NA 5 Dead 
R239C 4* NA 10 Dead 
R239C 5* NA 10 Dead 
R239C 6*  4 Dead 
R239H 14  1 Dead 
R239H 7* NA .6 Dead 
R258P 8* NA 6 Dead 
R416W 9* NA 6 Dead 
R416W 10* NA 8 Dead 
None 15  2 Dead 
None 11* NA .3 Dead 
a * p Patients reported by Brenner et al. (2001).
b  p Maximum head circumference 12 SD above the mean; NA
p not available.
c p Death after 110 years of disease or patient still alive without
macrocephaly after 5 years of disease;  p death after 5–10 years
of disease or patient still alive with macrocephaly after 1 year of dis-
ease; p death after 1–5 years of disease ; p death after
!1 year of disease; NR p not rated because of short duration of
disease.
R239C mutation had a less-severe clinical course than
that of the two patients with the R239H mutation, and
none of the eight patients has died before the age of 4
years (tables 1 and 2).
Both patients who had Alexander disease without
identified GFAP mutations (patient 11 of Brenner et al.
[2001] and patient 10 of the present work) had a his-
tologically proved diagnosis and a severe clinical form
of the disease. However, we have not yet rigorously ex-
cluded (1) mutations in the promoter or intronic se-
quences of the GFAP gene or (2) rearrangements of the
genomic region containing GFAP. On the other hand,
although GFAP gene mutations appear to be the pre-
dominant cause of infantile Alexander disease, it is pos-
sible that other genes may contribute, particularly in
patients with the most-severe (early infantile) or mildest
(juvenile and adult) forms of the disease (reviewed in
Messing et al. 2001). In other human genetic diseases
involving intermediate filaments, mutations have been
found in both the intermediate filament protein and as-
sociated proteins.
In all patients analyzed, the GFAP mutations are
dominant and arise de novo. Affected siblings whose
parents were unaffected, including one family with neu-
ropathologically proved Alexander disease (Wohlwill
et al. 1959), could result from autosomal recessive
transmission or from germinal mosaicism for a domi-
nant mutation. Therefore, in patients with Alexander
disease who have de novo GFAP mutations, prenatal
diagnosis should be proposed for all further pregnan-
cies. Further GFAP analysis is needed to investigate
whether the inheritable dominant forms of Alexander
disease that have been described in two families, both
of which had late onsets after age 25 years (Howard
et al. 1993; Schwankhaus et al. 1995), are also asso-
ciated with GFAP mutations.
In conclusion, GFAP mutations are a reliable marker
for infantile Alexander disease diagnosed according to
neuropathological or MRI defined criteria. MRI abnor-
malities with the characteristic rostrocaudal gradient in
white matter signal provide a strong rationale for the
analysis of the GFAP gene, even in the absence of mac-
rocephaly or neurological deterioration, when other
causes of leukodystrophies have been ruled out.
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